Reaction

Injection Site Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,229 reports · 51 co-occurring drugs

As of the last recalculation, Injection Site Infection appears in 3,229 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is INTERFERON BETA-1B (PRR 51.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Interferon Beta-1B	147	51.7	52.1
Methylprednisolone Acetate	45	36.7	36.9
Naltrexone	109	23.6	23.6
Treprostinil	345	19.7	19.8
Interferon Beta-1A	413	15.7	15.7
Testosterone Cypionate	21	15.2	15.3
Glatiramer Acetate	114	12.7	12.7
Cabotegravir	15	12.0	12.0
Buprenorphine	163	11.9	11.9
Peginterferon Beta-1A	22	10.9	10.9
Tadalafil	145	9.7	9.7
Riociguat	45	9.0	9.0
Macitentan	94	9.0	9.0
Ambrisentan	129	6.9	6.9
Paliperidone Palmitate	32	6.5	6.5
Insulin Glulisine	10	6.4	6.4
Selexipag	25	6.3	6.3
Fremanezumab-Vfrm	11	6.2	6.2
Octreotide Acetate	29	6.1	6.2
Sildenafil	53	6.0	6.0
Epoprostenol	12	5.9	5.9
Asfotase Alfa	9	5.8	5.8
Metolazone	10	5.7	5.8
Leuprolide Acetate	65	5.5	5.5
Sildenafil Citrate	102	5.3	5.3
Bosentan	38	4.9	4.9
Acalabrutinib	9	4.8	4.8
Pegvaliase-Pqpz	6	4.7	4.7
Anakinra	11	4.3	4.3
Sildenafil Powder,	23	4.2	4.2
Botulinum Toxin Type A	7	3.6	3.6
Tolvaptan	8	3.6	3.6
Lanreotide Acetate	4	3.3	3.3
Medroxyprogesterone Acetate	25	3.3	3.3
Buprenorphine Hydrochloride, Naloxone Hydrochloride	12	3.2	3.2
Insulin Lispro	57	2.7	2.7
Ixekizumab	15	2.6	2.6
Onabotulinumtoxina	29	2.4	2.4
Peginterferon Alfa-2A	20	2.4	2.4
Ribavirin	23	2.3	2.3
Sarilumab	9	2.2	2.2
Alteplase	5	2.1	2.1
Etanercept	187	2.1	2.1
Tirzepatide	51	2.1	2.1
Suvorexant	4	2.0	2.0
Exenatide	16	2.0	2.0
Galcanezumab-Gnlm	9	1.8	1.8
Alirocumab	6	1.5	1.5
Dulaglutide	17	1.2	1.2
Bimekizumab	4	1.2	1.2
Etonogestrel	8	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.